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Abstract  
BACKGROUND: Coronary Artery Bypass Grafting (CABG) is realised in patients with critical or advanced 
disease of coronary arteries. There are different pharmacotherapeutic approaches which are used as 
management, treatment and preventive therapy in cardiovascular disease or related comorbidities. Performing a 
successful surgery, pharmacotherapy, and increase of bypass patency rate remains a serious challenge. 
AIM: This study aims to analyse the patient characteristics undergoing CABG and evaluation of their drug 
utilisation rate and daily dosages in the perioperative period. 
MATERIAL AND METHODS: Data were collected from 102 patients in the period 2016-2017 and detailed 
therapeutic prescription and dosages, patient characteristics were analysed before the operation, after the 
operation and visit after operation in the Clinic of Cardiac surgery-University Clinical Center of Kosovo. 
RESULTS: Our findings had shown that patients provided to have normal biochemical parameters in the clinic 
before the operation, and were related to cardiovascular diseases and comorbidities and risk factors with mainly 
elective intervention. The, however, higher utilisation of cardiovascular drugs such as beta blockers, diuretics, 
anticoagulants, statins and lower calcium blockers, ACEi, ARBs, hydrochlorothiazide, amiodarone were founded. 
ARBs, beta blockers, statins, nitrates and nadroparin utilisation decreased after operation and visit after the 
operation, whereas amiodarone only in the visit after the operation. Diuretics are increased after the operation 
which decreases in the visit after the operation. Regarding the daily dosage, only metoprolol was increased in the 
visit after operation (P < 0.001) and visit after operation (P < 0.05) whereas losartan and furosemide were 
increased (P < 0.01) and (P < 0.05) respectively. 
CONCLUSION: The study showed that beta blockers, statins, aspirin, nitrates (before the operation), furosemide 
and spironolactone are the most utilised drugs. However, we found low utilisation rate for ACEi, ARBs, 
clopidogrel, nadroparin, warfarin, xanthines, amiodarone, calcium blockers. Daily dosages were different 
compared to before CABG only in metoprolol, losartan, and furosemide. 
 
 
 
 
Introduction 
 
Cardiovascular diseases are the biggest 
cause of mortality and are mostly related to the 
coronary heart being also higher rate cause of 
morbidity cross-linked with ischemic heart disease 
and neurologic damages from cerebral haemorrhages 
[1] [2] [3]. In atherosclerosis, the main mechanism of 
worsening of the disease remains to inflammatory 
processes during the atherogenesis [4]. Also, lipid 
deposits and oxidised phospholipids are involved in 
many processes such as endothelium dysfunction, 
activation of adhesive molecules, chemotactic factors 
which promote interactions between leukocytes and 
endothelium, tissue factor releases and activation of 
coagulation cascades up to atherothrombotic 
formation [5] [6]. 
Epidemiologic studies provided that diabetes 
mellitus, hypertension, and lifestyle with high lipid 
intake, stress, and sedentary life are the main triggers 
for the appearance of the disease [7]. Due to this 
pharmacotherapeutic approaches with antithrombotic, 
antiaggregant, hypolipidemic, anti-inflammatory, 
vasorelaxant, antihypertensive, percutaneous 
coronary interventions and cardiovascular surgeries 
including coronary artery bypass grafting (CABG) 
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regarding prevention and treatment of cardiovascular 
diseases, atherosclerosis and endothelial dysfunction 
and critically advanced stages of coronary artery 
diseases are improving [8] [9]. 
Patients with stenosed arteries that undergo 
CABG are mostly realized with saphenous vein (SV), 
mammary or radial artery grafts and provides 
improvement of angina symptoms, better quality of life 
and survival rates [10], while there is also difference 
between the type of grafts in terms of susceptibility to 
atherosclerosis, occlusion, and failure of grafts which 
mostly included SV as more sensitive to these 
pathophysiologic processes [11]. Therefore based on 
these facts among the main problems which are still 
appeared in patients undergoing CABG are graft 
failure and occlusion also related with the 
atherothrombotic formation, increased vasospastic 
agents which play a role in early and late phases of 
these interventions [12] [13]. The survival rate is 
higher in left internal mammary artery grafts and radial 
artery [14] [15]. 
There are different study approaches 
regarding management of perioperative symptoms 
and diseases by interfering in graft tissues 
pathophysiology which increase CABG patency rate 
and reduce operation complications. These groups of 
patients are recommended to use multiple 
pharmacotherapeutic agents to prevent perioperative 
complications [8]. Main therapies are antithrombotic, 
antiaggregant and anticoagulant drugs such as 
aspirin, clopidogrel, tirofiban, eptifibatide, enoxaparin, 
nadroparin, bivalirudin, fondaparinux and are limited 
regarding the different perioperative period due to 
increased risk of bleeding. Also other antihypertensive 
groups such as hypolipidemic including statins, beta-
blockers, Angiotensin Converting Enzyme Inhibitors 
(ACEi), Angiotensin Receptor Blockers (ARBs). 
The underutilization (lower than 50 %) of 
these drugs in postoperative discharge have shown 
an increased risk of myocardial infarction and death 
[16] [17]. 
Therefore the strategies for their standardised 
utilisation of these drugs in CABG are essential 
factors to reduce the risk of coronary diseases and 
improving the survival rate of the patients [18]. Use of 
antiaggregant in the early postoperative period have 
improved the life expectancy of coronary bypass and 
cardiovascular-related symptoms, reduced graft 
occlusion [19], while other anticoagulants such as 
warfarin are shown to play a role in patients with atrial 
fibrillation or with thromboembolism history [20]. 
Statins are used unless contraindicated in patients 
before and after operation [21]. 
Beta-Blockers utilisation is found more in 
postoperative atrial fibrillation prevention, 
hypertension [22], while ACEi is used more in 
myocardial infarction, left ventricular dysfunction, 
diabetes mellitus, chronic renal dysfunction. Also, 
calcium-blockers and diuretics are used for 
hypertension control. 
Summarizing this number of patients affected 
by the cardiovascular disease in Kosovo is increasing 
and in particular, a considered number undergoing 
CABG exists. Moreover, pharmacotherapeutic 
evaluation is a necessary approach and intervention 
in perioperative procedures with the aim to reduce 
complications and increase the bypass patency and 
survival rate. Therefore, we aim to evaluate the drug 
utilisation rate in the perioperative state (before, after 
and after the visit) undergoing CABG and also identify 
targets for quality improvement with the preparation of 
guidelines and protocols for prudent use of drugs in 
cardiovascular surgery. 
 
 
Material and Methods 
 
This study is prospective observational study 
realised in 102 selected patients undergoing CABG in 
the period of hospitalisation in the Cardiovascular 
Surgery Clinic at the University Clinical Center of 
Kosovo (Prishtina, Kosovo) between the year 2016-
2017. 
The procedures in this study were conducted 
according to guidelines in the Declaration of Helsinki, 
and the study design was approved by Ethics 
Committee in Faculty of Medicine (Nr: 3625), 
University of Prishtina, Hasan Prishtina and University 
Clinical Center of Kosovo (Pristina, Kosovo). 
Patients were selected from the randomly 
selected subset of the study cohort to assess 
medication and participation were voluntary.  The 
sample size also fits calculation of sample size was 
performed using Raosoft software with a 5% margin of 
error, a 95% confidence level, and a 50% response 
distribution. Since the undergoing coronary artery 
bypass grafting patients in Kosovo was 120-150 in 
previous years. In this analysed year, total numbers in 
this period were 134 patients in this analysed year 
(according to the Hospital Statistics), which are in line 
sample size 102. Patients with a combination of 
operations, the absence to visit after the operation 
and those that did not survive the intervention after 
surgery were not included in our study. 
Data were collected by the clinical 
pharmacologist, pharmacist and cardiac surgeon with 
properly designed form sheet. The drug use 
evaluation involved the therapy prescription and daily 
dosages in each patient, before the operation in the 
clinic, in the discharge after the operation and after the 
first visit in the clinic (≈ 2 months). The characteristics 
of patients such as age, gender, related comorbidities, 
metabolic and cardiovascular diseases, risk factors 
were collected. 
The number of bypass arteries or veins and 
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priority of the intervention and available clinical 
indicated biochemical parameters in the period 
previous surgery such as Triglycerides, Cholesterol, 
Creatinine, AST, ALT, C-Reactive Protein (CRP), Left 
Ventricular Ejaculation Fraction (LVEF) were 
registered. 
The general data's in the tables are 
expressed as prevalence or mean values. Drug use 
and daily dosages were calculated as (%) within each 
group. 
Two sampled t-test were used for the 
comparison between the data between analysed 
groups regarding drug utilisation, whereas One-way 
ANOVA for comparison between the daily therapeutic 
dosages from each group or unpaired student t-test 
for differences between the two groups. 
P value lower than 0.05 was considered 
statistically significant and represented the significant 
differences between the analysed groups. All analysis 
was performed using statistical software GraphPad 
PRISM (version 6.0). 
 
 
Results 
 
The study included data of 102 patients, aged 
62.2 ± 10.3 with woman consulting 24% of the group 
analysed. The comorbidities in our study were Arterial 
Hypertension 67%, Angina Pectoris 42%, Type 2 
Diabetes Mellitus 41%, Hypertriglyceridemia 21% and 
Hypercholesterolemia 18%. In our study, 36% were 
not smoking while 0-10 years smokers were 4%, 10-
20 years 11%, 20-30 years 16% and 40-50 years 
30%. 
Table 1: Patient characteristics 
Demographic and Clinical Patient Characteristics 
Gender (M/F) 78/24 
Age  62.2 ± 10.3 
Angina Pectoris 42 (%) 
Hypercholesterolemia 18 (%) 
Hypertriglyceridemia 28 (%) 
Diabetes Mellitus  41 (%) 
Hypertension 67 (%) 
 
Smokers (before/now) 
     a) 0 years        (36%) 
   b) 1-10 years   (4%) 
     c) 10-20 years (11%) 
     d) 20-30 years (16%) 
     e) 30-40 years (30%) 
 
Indication for angiography was included in all 
of our analyzed patients, and there was no previous 
CABG found, Cerebrovascular diseases (ischaemic 
disease, stroke and carotid stenosis) were widespread 
in 6 % of patients, whereas peripheral artery diseases 
(microvascular and macrovascular including varicose 
veins) 25%, left main coronary artery occlusion was 
present in 15%, and 17% of patients were with post-
myocardial infarction status. Chronic renal failure was 
only 3% patients while 10% were with low degree 
renal insufficiency. Based on the priority of 
intervention, only 18% of patients were in urgency for 
cardiovascular surgery whereas 85% of patients were 
elective cases. Graft bypass results from the left 
internal mammary artery and SV. Demographics and 
clinical characteristics regarding cardiovascular 
disease, comorbidities, risk factors including smoking, 
type of intervention, the priority of intervention and 
type of graft data are featured in (Table 1 and 2). 
Table 2: Patient characteristics regarding cardiovascular 
disorders and CABG intervention 
 
Cardiovascular Characteristics of Patients in CABG 
 
Indication for coronary angiography            100 (%) 
Previous CABG                0 (%) 
Cerebrovascular disease                6 (%) 
Peripheral artery disease              25 (%) 
Left Main Coronary Artery Occlusion              15 (%) 
Status post IM              17 (%) 
Chronic Obstructive Pulmonary Disease                5 (%) 
Chronic Renal Insufficiency/Renal Insufficiency           3/10 (%) 
CABG type ( CABG Isolated/Combination)          100/0 (%) 
Intervention Priority (Urgency/Elective)          18/82 (%) 
Arteries (LIMA) Vein (VSM) for CABG  (5/4/3/2)                  1/29/48/18 (%) 
 
Biochemical parameters and cardiovascular 
data were within normal range values in all 
investigated patients as shown in the (Table 3), even 
though CRP values were in borderline, the specificity 
also exists for in individual values with higher AST and 
ALT values in 11% of patients, CRP higher values in 
14% of patients, Creatinine in 10% of patients (data 
not shown). 
Table 3: General biochemical - cardiovascular parameters of 
patients undergoing CABG 
Biochemical/Cardiovascular Parameters 
Triglycerides (mmol/L) 1.83 ± 0.9 
Cholesterol  (mmol/L) 3.64 ± 1.1 
Creatinine (µmol/L) 102.9 ± 15.8 
AST (U/L) 28.2 ± 12.3 
AST (U/L) 31.1 ± 14.5 
CRP mg/dL 6.2 ± 4.8 
Left Ventricular Ejaculation Fraction (%) 53.7 ± 10.9 
 
The cardiovascular system drug utilisation 
rates in CABG patients in the period before the 
operation, after operation and visit after the operation 
are shown in the (Table 4). 
Table 4: Cardiovascular pharmacological treatment 
administered in CABG Patients 
Drug Utilization Rates in CABG Patients 
Type of Drugs Before Operation 
(%) 
After Operation (%) Visit after Operation 
(%) 
Beta Blockers 77.1 48.2 59.1 
Calcium Blockers 4.9 9.6 8.1 
ACEi 31.3 30.1 23.5 
ARBs 22.9 3.6 8.5 
Hydrochlorothiazide 25.2 1.6 15.6 
Furosemide 15.7 97.6 52.8 
Spironolactone 12.2 91.6 70.1 
Nitrates 77.1 1.6 10.2 
Xanthines 7.3 19.3 7.3 
Statins 86.7 62.7 64.5 
Amiodarone 1 21.8 8.8 
Digitoxin 4.9 6.1 8.9 
 
Moreover, the other drug utilisation 
administered for the treatment and management of 
CABG patients are shown in (Table 5). 
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Table 5: Other pharmacological treatment administered in 
CABG Patients 
Drug Utilization Rates in CABG Patients 
Type of Drugs Before Operation 
(%) 
After Operation (%) Visit after Operation 
(%) 
Warfarin 0.5 4.8 0.5 
Nadroparin 100 0.5 9.8 
Clopidrogrel 0.5 33.8 21.9 
Aspirin 0.5 97.6 76.5 
IPP 49.4 65.1 51.8 
H2 Blockers 37.4 35.5 38.5 
Acetaminophen 4.8 35.5 12.2 
76.5Indomethacin 0 14.5 7.3 
Acetilcystine 2.4 72.3 11.8 
Anxiolytics 6.5 4.9 4.9 
Ceftriaxone 14.5 100 21.1 
Insulins 32.5 42.2 27.9 
Supplements 1 33.7 17.7 
 
The daily dosage rates from the widely 
prescribed groups such as beta-blockers, ACEi, and 
ARBs, Diuretics are shown in (Figure 1-3).   
 
Figure 1: Drug Utilization Rates expressed as daily dosage 
(mg/day) of beta blockers: Before CABG; After CABG and Visit after 
CABG. * P < 0.05, ** P < 0.01, *** P < 0.001 
 
In beta blockers only metoprolol dosages are 
increased after the operation (P<0.001), and de-
creased in the visit after operation (P<0.05) (Figure 1). 
 
Figure 2: Drug Utilization Rates expressed as daily dosage 
(mg/day) of ACEi/ARBs: Before CABG; After CABG and Visit after 
CABG. * P < 0.05, ** P < 0.01, *** P < 0.001 
 
From the ACEi or ARBs, only daily dosages of 
losartan were increased in the visit after the operation 
(P<0.01) (Figure 2), whereas in diuretics furosemide 
dosage was increased only in the period after the 
operation (P<0.05) (Figure 3). 
 
Figure 3: Drug Utilization Rates expressed as daily dosage 
(mg/day) of Diuretics: Before CABG; After CABG and Visit after 
CABG. * P < 0.05, ** P < 0.01, *** P < 0.001 
 
The daily dosages regarding statins, antiacids 
(IPP and H2 Blockers), amiodarone are within the 
therapeutic values, but when compared from our 
analysed study groups they remain to be unchanged 
(P>0.05) (data not shown). 
 
 
Discussion 
 
In the present study, most of the patients 
were affected by cardiovascular diseases and 
comorbidities such as angina pectoris, 
hypercholesterolemia, hypertriglyceridemia, diabetes 
mellitus, hypertension and risk factors including 
smoking as observed in other studies [23].  
Moreover, arterial diseases were also present 
including status post myocardial infarction, left main 
coronary artery occlusion, rare cases of 
cerebrovascular disease such as ischaemic stroke 
and carotid stenosis and renal failure and 
insufficiency. Elective patients have dominated, and 
SV was used more compared to a left internal 
mammary artery for the bypass grafting. Biochemical 
parameters previous intervention were within the 
normal ranges however there was a low number of 
patients which were presented with abnormal 
measured values. Left ventricular ejaculation fraction 
was standard in all analysed patients at a similar level 
to other reports [24] [25]. 
Pharmacotherapeutic evaluation has shown 
an increasing number of drugs in all groups 
corresponding three monitoring phases. The beta 
blockers were utilised with 77% before the operation, 
48% after the operation and 59% visit after the 
operation. Metoprolol is the most prescribed 
medication with a higher dosage in the postoperative 
period. This data are in line with other previous 
findings [18]. Also, the higher utilisation in the 
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preoperative period was shown to improve clinical 
outcomes by reducing the number of complications 
and total mortality [26]. However, there are 
contradictory reports in beta blockers users which 
showed the no beneficial effect of beta-blockers in the 
clinical outcomes and mortality, even though the 
underutilization of beta blockers (30%) were lower 
when compared with our data [27]. Another study 
performed in the larger number of patients from the 
national database analysis in the including no 
emergent and without previous MI patients showed 
not to be favourable in the reduction of perioperative 
complications. However, the preoperative utilisation 
rates of beta-blockers were pretty similar to our 
findings [28].  
Additional studies with the use of the beta 
blockers in the secondary prevention after CABG 
showed lower death and myocardial infarction rate 
and are found to be suboptimal with reduction rate 
from 89 after discharge and 77% after one year [17]. 
Also, the higher rates of utilisation of beta-blockers 
have been shown in other related studies (94%) [29] 
[30], which are not in agreement with our data.   
In continuity ACEi drug utilisation rates were 
(31%, 30%, and 24%) and for ARBs (23%, 4%, and 
9%), hydrochlorothiazide (23%, 2%, and 16%), which 
show a decreasing trend in postoperative and after 
the first visit. Only losartan daily dosage was 
increased in the visit after the operation. Our data are 
not by previous findings which showed increased 
utilisation rates of the ACEi/ARBs in postoperative 
CABG period, even though no effect were observed 
regarding death and re-hospitalisation for 
cardiovascular events [17] [30]. Also, the pre-
operative utilisation of ACEi is shown to be higher 
compared to our data (30% vs 50%) which still did not 
reflect the in the improvement of clinical outcomes or 
adverse events (with the only increased risk of 
readmission for heart failure) [31]. Moreover, in 
another related study, the pre-operative utilisation of 
ACEi was 45 % with an increased number of the 
major adverse events (in particular renal dysfunction 
and atrial fibrillation) without an impact in mortality, 
stroke and myocardial infarction [32].  
Diuretics such as furosemide and 
spironolactone utilisation were increased in the period 
after the operation, with slowly decreasing in the visit 
after operation (16%, 98%, and 53%) and (12%, 92%, 
and 70%). The daily dosage of furosemide was 
increased only after the operation. Also, the diuretic 
use was found to be in line with our data, and 
increased reports of major adverse events suggest 
their utilisation reduction before surgery (excluding to 
higher clinical evidence) [33]. 
Moreover antiaggregant drugs such as aspirin 
and clopidogrel were interrupted a week before 
operation in all patients, hence the utilization of them 
were continued after operation and in the visit after 
operation with (98% and 77%) for aspirin, (34 and 
22%) for clopidogrel which underlies that the 
combination of dual antiplatelet therapy was not as 
reported studies [27], whereas the anticoagulant 
therapy with nadroparin has dominated only in the 
period before the operation. The daily dosages were 
similar in all groups. 
Our data are by other findings in the 
antiaggregant drug utilisation in related studies by 
showing an increased utilisation in the postoperative 
operative period suggesting their preventive role and 
lower long-term cardiovascular events [17] [34]. 
Utilization of hypolipidemic drugs including 
statins were reduced after operation (87%, 63%, and 
65%) however proportional daily dosages were found, 
which are in line with other recommendation which 
emphasises their continuity in the period after 
operation [35]. 
The increased utilisation rates of statins are 
recommended for the further improvement of 
cardiovascular clinical outcomes, perioperative and 
postoperative complications, inflammation [36]. Their 
postoperative use is also shown to be higher utilised 
and was associated with reducing recurrent ischaemic 
events and mortality [17] [29] [30], which were not by 
our findings due to their underutilization in the period 
after CABG. Moreover, according to the recent study, 
the loading dose of statins in the period after CABG is 
shown to be superior to regular dose regarding 
cardiovascular events and without proof of serious 
adverse events which might reflect their strategy in 
the dosing guidelines and prescribing in the future 
[21].  
Based on our findings the utilisation of aspirin, 
beta-blockers, statins are comparable also with other 
related studies while ACEi/ARBs are underutilised in 
our study [18]. However, our findings are in line also in 
the utilisation of beta blockers, aspirin, ACE, higher in 
statin and underutilization nitrates [37]. In another 
study, the secondary prevention in patients 
undergoing coronary bypass, the utilisation of beta 
blockers, aspirin, a statin was in agreement with our 
findings, excluding the lower rate of ACEi or ARBs 
[38]. Other reports after operation have shown similar 
trends in beta blockers, statin, with lower ACEi/ARBs 
which also potentiate the necessity for the 
optimisation of the drug use in the postoperative 
period [39]. A possible explanation regarding lower 
rates of ACEi/ARBs utilisation may be the normal 
values of left ventricular ejaculation fraction, even 
though these values were not higher as previous 
studies [40]. 
Moreover, one retrospective study was 
observed by providing the recorded clinical data in the 
period when patients were admitted and also in the 
discharge. In this study, the use beta blockers, aspirin, 
and statin were in similar range but with higher ACEi, 
lower ARBs (only before the operation) compared to 
our findings. It is worth mentioning the fact that 
utilisation of beta blockers, ACEi, statins were 
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decreasing in the analysed years, and ARBs were 
increasing in the period before operation whereas 
after operation beta blockers and statins were 
decreasing [41]. 
The antiaggregants such as aspirin was 
regularly used and in a standard dosage and not all 
patients were combined with clopidogrel as dual 
antiplatelet. 
Beta-blocker usage is in line with our data as 
recommended with previously reported guidelines for 
the pharmacotherapy after CABG [42]. However, 
ACEi or ARBs are not used properly in all patients due 
to normal LVEF in our study. Moreover, aldosterone 
antagonists need to be reevaluated due to their limited 
use in LVEF < 35% or cardiac insufficiency II-IV 
patients. Statin utilisation was not monitored properly 
and titrated in our study. 
Approximate data regarding existing protocol 
and evidence for the management of patients after 
CABG are also found in other guidelines from 
American heart association which also relies on the 
type of evidence and relevant treatment [8]. 
Other utilised drugs in our study were: 
vasodilators including nitrates with (77%, 2% and 
10%) and xanthines with (7%, 19% and 7%). Even 
though amiodarone utilisation were (1%, 18%, 7%) 
more should be done to replace it with beta blockers 
and also the use of statins with the magnesium in the 
same period [39]. Also, the use of amiodarone in the 
prevention of atrial fibrillation only 24 hours after 
operation intravenously and in lower dosages is 
another promising strategy [43]. 
Cardiovascular pharmacotherapeutic 
approaches in diabetes mellitus consisted usage of 
insulin which was accompanied with a reduction in the 
period after the operation, probably due to the 
increased risk of clinical features in patients with 
CABG [44]. 
Also, the antiacids such as IPP or H2 blockers 
are mainly used as prophylaxis regarding the surgical 
intervention which is a common indication [45] and 
decreases in the visit after the operation. Other drugs 
such as analgesics including acetaminophen are 
indicated as needed mostly in postoperative period 
with nonsteroidal anti-inflammatory drugs 
indomethacin, acetylcysteine dominated in the period 
after the operation and reduced in the visit after 
operation with also cephalosporin antibiotics. The 
frequency of NSAID administration after CABG has 
declined since the FDA recommendations and advice 
due to safety concerns and from 2004 (39%) to 2010 
(29%) which may also impact the lower utilization in 
our group of patients (15%) [46], also the higher 
utilization of acetylcysteine need to be also 
considered to its scientific evidence in the prevention 
of atrial fibrillation to undergoing CABG patients [47]. 
Rare cases of digoxin, trimetazidine, 
tamsulosin, doxazosin, levotiroksin, fluoxetine, 
metformin, and ipratropium-budesonide were also 
founded. 
In the meantime with our study regarding 
utilisation and daily dosages, we have also performed 
experimental studies for the alternative in compounds 
(arctigenin) for vasorelaxation and decreasing 
inflammation level in SV tissues [23]. 
In addition to this omega 3 polyunsaturated 
fatty acids were shown to be beneficial in 
inflammation and contractility in SV tissues [48]. 
There are undergoing similar approaches by 
other groups by investigating endothelin-1 antagonists 
[49], levosimendan [50], anti-ischaemic agents 
including ranolazine were shown to improve 
postoperative fibrillation in patients after CABG [40], 
and additional pharmacologic agents which inhibit the 
vasospasm of coronary grafts [51]. 
The drug utilisation after CABG have shown 
to be an important factor regarding long-term 
management of the clinical outcomes, the adherence 
of this drugs were not satisfactory after the first year 
after the revascularisation period [29], which suggests 
different strategies and interventions increase the 
improvements of clinical outcomes and bypass 
patency rates.  
Despite the clinical relevance of this study,  
the absence of official protocols which are in the 
procedure of establishment to maintain effective use 
of drugs  may affect drug prescription and utilization, 
long-term monitoring (more than three months) after 
CABG, short period of study (for 1-5 years after 
CABG) and the adherence monitoring after discharge 
including also clinical outcomes and adverse events 
could be considered as a limitations of our study. 
Taking this into consideration our work may set the 
stage for larger investigational studies aimed at 
evaluating the utilisation and also drug adherence, 
long-term monitoring including also the long period 
after the discharge and clinical outcomes and adverse 
events.  
In summary in our study, we have found that 
therapeutic groups such as beta blockers, statins, 
aspirin, thiazides, nitrates (before the operation), 
furosemide and spironolactone are the most utilised 
drugs. However, we found low utilisation rate for 
ACEi, ARBs, clopidogrel, nadroparin, warfarin, 
xanthines, amiodarone, calcium blockers. Daily 
dosages were different compared to before CABG 
only in metoprolol, losartan, and furosemide. 
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